BCM
VIR icon

Bayesian Capital Management’s Vir Biotechnology VIR Stock Holding History

Bayesian Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,226
Closed -$98.7K – 893
2025
Q1 		$98.7K Buy
+15,226
New +$135K 0.02% 543
2024
Q2 		– Sell
-25,600
Closed -$259K – 1121
2024
Q1 		$259K Buy
+25,600
New +$261K 0.02% 594
2022
Q1 		– Sell
-5,540
Closed -$232K – 932
2021
Q4 		$232K Buy
+5,540
New +$217K 0.07% 297

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bayesian Capital Management's VIR Position: Q2 2025 in Review

Bayesian Capital Management sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 15,226 shares — an estimated $98.7K sold.

Bayesian Capital Management first reported a position in VIR in Q4 2021 and held it in 3 quarters. The position peaked at $259K in Q1 2024. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Bayesian Capital Management reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 15,226 Vir Biotechnology shares in Q2 2025, an estimated $98.7K.
  • Bayesian Capital Management first reported a position in Vir Biotechnology in Q4 2021 and held it in 3 quarters.
  • Bayesian Capital Management's Vir Biotechnology position peaked at $259K in Q1 2024.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Bayesian Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.